BACKGROUND: COPD exacerbations are important events for disease management. The incidence of exacerbations impacts prognosis, guides treatment, and predicts future exacerbations. Despite their importance, exacerbations are often underdiagnosed and underreported. The aim of our study was to test and evaluate the effectiveness of a structured checklist for detecting past exacerbations that we developed and that would be suitable for routine clinical practice. METHODS: 350 patients with COPD and FEV1 < 80% of the predicted value were enrolled in 35 centers. Each patient completed a structured checklist and underwent an interview with the physician. The number of exacerbations, their symptoms and duration, and the treatments were evaluated. Clinical data on exacerbations in the previous 12 months were retrieved from the patient's medical records and analyzed retrospectively. The data obtained using the structured checklist were compared with the data from the interviews and medical records. RESULTS: Compared to the patient-physician interview, the structured checklist detected more exacerbations since the previous visit (p = 0.025). The difference was significant also for severe exacerbations (p = 0.003). In patients reporting only one event, the structured checklist was more sensitive in detecting mild events than the interview (p < 0.001). The structured checklist detected mild exacerbations in 10 patients in whom the interview detected none. Compared to the number of exacerbations in the medical records, the structured checklist detected more than twice as many events. The mean duration of an exacerbation was 9.7 days, and the most prominent symptoms were dyspnea and productive cough. CONCLUSION: Proposed structured checklist improved the detection of past exacerbations, including usually unreported events. Moreover, the structured checklist allows the severity and other clinical characteristics of past exacerbations to be specified and used to direct further COPD therapy.

AstraZeneca Czech Republic Prague Czechia

Department of Pneumology University Hospital Hradec Kralove Hradec Kralove Czechia

Department of Respiratory Medicine University Hospital Olomouc Olomouc Czechia

Faculty of Medicine and Dentistry Palacky University Olomouc Czechia

Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czechia

Zobrazit více v PubMed

2025 GOLD Report . (2024) Global initiative for chronic obstructive lung disease - GOLD. https://goldcopd.org/2025-gold-report/ [Accessed December 29, 2024]

Zatloukal J, Brat K, Neumannová K, et al. Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological society. Biomed Pap. (2020) 164:325–56. doi: 10.5507/bp.2020.056, PMID: PubMed DOI

Voláková E, Koblížek V, Svoboda M, Zatloukal J, et al. Nutritional status and muscle mass loss in patients with COPD, association with lung function, symptoms, comorbidities and long-term survival: data from the National Database Study. Biomed Pap. (2025) 169:XX. doi: 10.5507/bp.2025.001, PMID: PubMed DOI

Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. (2005) 60:925–31. doi: 10.1136/thx.2005.040527, PMID: PubMed DOI PMC

Whittaker H, Rubino A, Müllerová H, Morris T, Varghese P, Xu Y, et al. Frequency and severity of exacerbations of COPD associated with future risk of exacerbations and mortality: a UK routine health care data study. Int J Chron Obstruct Pulmon Dis. (2022) 17:427–37. doi: 10.2147/COPD.S346591, PMID: PubMed DOI PMC

Villegas CG, Paz-Zulueta M, Herrero-Montes M, Parás-Bravo P, Pérez MM. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. Health Econ Rev. (2021) 11:31. doi: 10.1186/s13561-021-00329-9, PMID: PubMed DOI PMC

Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. (2010) 363:1128–38. doi: 10.1056/NEJMoa0909883, PMID: PubMed DOI

Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD – a review of potential interventions. Int J Chron Obstruct Pulmon Dis. (2009) 4:203–23. doi: 10.2147/COPD.S3385, PMID: PubMed DOI PMC

Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. (2008) 177:396–401. doi: 10.1164/rccm.200708-1290OC, PMID: PubMed DOI

Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. (2017) 50:1700711. doi: 10.1183/13993003.00711-2017, PMID: PubMed DOI PMC

Agustí A, Soler JJ, Molina J, Muñoz MJ, García-Losa M, Roset M, et al. Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations? COPD. (2012) 9:492–8. doi: 10.3109/15412555.2012.692409, PMID: PubMed DOI

Oliveira AS, Munhá J, Bugalho A, Guimarães M, Reis G, Marques A. Identification and assessment of COPD exacerbations. Pulmonology. (2018) 24:42–7. doi: 10.1016/j.rppnen.2017.10.006, PMID: PubMed DOI

Johnston NW, Lambert K, Hussack P, de Verdier MG, Higenbottam T, Lewis J, et al. Detection of COPD exacerbations and compliance with patient-reported daily symptom diaries using a smartphone-based information system. Chest. (2013) 144:507–14. doi: 10.1378/chest.12-2308, PMID: PubMed DOI PMC

Côté J, Cartier A, Malo JL, Rouleau M, Boulet LP. Compliance with peak expiratory flow monitoring in home Management of Asthma. Chest. (1998) 113:968–72. doi: 10.1378/chest.113.4.968, PMID: PubMed DOI

Chowienczyk PJ, Parkin DH, Lawson CP, Cochrane GM. Do asthmatic patients correctly record home spirometry measurements? BMJ. (1994) 309:1618. doi: 10.1136/bmj.309.6969.1618, PMID: PubMed DOI PMC

Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials. (2003) 24:182–99. doi: 10.1016/s0197-2456(02)00320-3, PMID: PubMed DOI

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N Engl J Med. (2016) 374:2222–34. doi: 10.1056/NEJMoa1516385 PubMed DOI

Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group study. Lancet Respir Med. (2013) 1:199–209. doi: 10.1016/S2213-2600(13)70052-3, PMID: PubMed DOI

Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. (2011) 183:323–9. doi: 10.1164/rccm.201005-0762OC, PMID: PubMed DOI

Mackay AJ, Donaldson GC, Patel ARC, Singh R, Kowlessar B, Wedzicha JA. Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J. (2014) 43:735–44. doi: 10.1183/09031936.00110913, PMID: PubMed DOI

Vogelmeier CF, Diesing J, Kossack N, Pignot M, Friedrich FW. COPD exacerbation history and impact on future exacerbations – 8-year retrospective observational database cohort study from Germany. Int J Chron Obstruct Pulmon Dis. (2021) 16:2407–17. doi: 10.2147/COPD.S322036, PMID: PubMed DOI PMC

Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation in COPD exacerbations. Int J Chron Obstruct Pulmon Dis. (2014) 9:1101–10. doi: 10.2147/COPD.S54475, PMID: PubMed DOI PMC

Aaron SD. Measuring and quantifying acute exacerbations of COPD: pitfalls and practicalities. Eur Respir J. (2014) 43:662–4. doi: 10.1183/09031936.00158613, PMID: PubMed DOI

Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. (1987) 106:196–204. doi: 10.7326/0003-4819-106-2-196, PMID: PubMed DOI